메뉴 건너뛰기




Volumn 29, Issue 9, 2007, Pages 598-601

Urinary iron excretion in young thalassemic patients receiving combined chelation treatment with deferoxamine and deferiprone

Author keywords

thalassemia major; Combined therapy; Deferiprone; Deferoxamine; Urinary iron excretion

Indexed keywords

DEFERIPRONE; DEFEROXAMINE;

EID: 34548384760     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e318142b51e     Document Type: Article
Times cited : (9)

References (18)
  • 2
    • 0031001278 scopus 로고    scopus 로고
    • Iron-chelating therapy and the treatment of thalassemia
    • Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. Blood. 1997;89:739-761.
    • (1997) Blood , vol.89 , pp. 739-761
    • Olivieri, N.F.1    Brittenham, G.M.2
  • 3
    • 14544288577 scopus 로고    scopus 로고
    • Deferiprone therapy for transfusional iron overload
    • Victor Hoffbrand A. Deferiprone therapy for transfusional iron overload. Best Pract Res Clin Haematol. 2005;18:299-317.
    • (2005) Best Pract Res Clin Haematol , vol.18 , pp. 299-317
    • Victor Hoffbrand, A.1
  • 5
    • 29744447450 scopus 로고    scopus 로고
    • Combined therapy with deferoxamine and deferiprone
    • Kattamis A. Combined therapy with deferoxamine and deferiprone. Ann N Y Acad Sci. 2005;1054:175-182.
    • (2005) Ann N Y Acad Sci , vol.1054 , pp. 175-182
    • Kattamis, A.1
  • 6
    • 0034783438 scopus 로고    scopus 로고
    • Chelation therapy in beta-thalassemia: An optimistic update
    • Giardina PJ, Grady RW. Chelation therapy in beta-thalassemia: an optimistic update. Semin Hematol. 2001;38:360-366.
    • (2001) Semin Hematol , vol.38 , pp. 360-366
    • Giardina, P.J.1    Grady, R.W.2
  • 7
    • 27144560152 scopus 로고    scopus 로고
    • Combined therapy with deferiprone and desferrioxamine in thalassemia major
    • Origa R, Bina P, Agus A, et al. Combined therapy with deferiprone and desferrioxamine in thalassemia major. Haematologica. 2005;90:1309-1314.
    • (2005) Haematologica , vol.90 , pp. 1309-1314
    • Origa, R.1    Bina, P.2    Agus, A.3
  • 8
    • 0034928342 scopus 로고    scopus 로고
    • Exploring the "iron shuttle" hypothesis in chelation therapy: Effects of combined deferoxamine and deferiprone treatment in hypertransfused rats with labeled iron stores and in iron-loaded rat heart cells in culture
    • Link G, Konijn AM, Breuer W, et al. Exploring the "iron shuttle" hypothesis in chelation therapy: effects of combined deferoxamine and deferiprone treatment in hypertransfused rats with labeled iron stores and in iron-loaded rat heart cells in culture. J Lab Clin Med. 2001;138:130-138.
    • (2001) J Lab Clin Med , vol.138 , pp. 130-138
    • Link, G.1    Konijn, A.M.2    Breuer, W.3
  • 9
    • 0347363715 scopus 로고    scopus 로고
    • Combined therapy with desferrioxamine and deferiprone in thalassemic patients: Effect on urinary iron excretion
    • Kattamis A, Kassou C, Berdousi H, et al. Combined therapy with desferrioxamine and deferiprone in thalassemic patients: effect on urinary iron excretion. Haematologica. 2003;88:1423-1425.
    • (2003) Haematologica , vol.88 , pp. 1423-1425
    • Kattamis, A.1    Kassou, C.2    Berdousi, H.3
  • 10
    • 84908219488 scopus 로고
    • Statistical methods for assessing agreement between two methods of clinical measurement
    • Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986;1:307-310.
    • (1986) Lancet , vol.1 , pp. 307-310
    • Bland, J.M.1    Altman, D.G.2
  • 11
    • 0031784438 scopus 로고    scopus 로고
    • Combined therapy with deferiprone and desferrioxamine
    • Wonke B, Wright C, Hoffbrand AV. Combined therapy with deferiprone and desferrioxamine. Br J Haematol. 1998;103:361-364.
    • (1998) Br J Haematol , vol.103 , pp. 361-364
    • Wonke, B.1    Wright, C.2    Hoffbrand, A.V.3
  • 12
    • 0242584372 scopus 로고    scopus 로고
    • Comparison between desferrioxamine and combined therapy with desferrioxamine and deferiprone in iron overloaded thalassaemia patients
    • Mourad FH, Hoffbrand AV, Sheikh-Taha M, et al. Comparison between desferrioxamine and combined therapy with desferrioxamine and deferiprone in iron overloaded thalassaemia patients. Br J Haematol. 2003;121:187-189.
    • (2003) Br J Haematol , vol.121 , pp. 187-189
    • Mourad, F.H.1    Hoffbrand, A.V.2    Sheikh-Taha, M.3
  • 13
    • 33646677440 scopus 로고    scopus 로고
    • Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload
    • Daar S, Pathare AV. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload. Ann Hematol. 2006;85:315-319.
    • (2006) Ann Hematol , vol.85 , pp. 315-319
    • Daar, S.1    Pathare, A.V.2
  • 14
    • 33745531237 scopus 로고    scopus 로고
    • Effective combination therapy of deferiprone and deferoxamine for the rapid clearance of excess cardiac IRON and the prevention of heart disease in thalassemia. The Protocol of the International Committee on Oral Chelators
    • Kolnagou A, Kontoghiorghes GJ. Effective combination therapy of deferiprone and deferoxamine for the rapid clearance of excess cardiac IRON and the prevention of heart disease in thalassemia. The Protocol of the International Committee on Oral Chelators. Hemoglobin. 2006;30:239-249.
    • (2006) Hemoglobin , vol.30 , pp. 239-249
    • Kolnagou, A.1    Kontoghiorghes, G.J.2
  • 15
    • 33748742706 scopus 로고    scopus 로고
    • Combined chelation therapy improves glucose metabolism in patients with beta-thalassaemia major
    • Christoforidis A, Perifanis V, Athanassiou-Metaxa M. Combined chelation therapy improves glucose metabolism in patients with beta-thalassaemia major. Br J Haematol. 2006;135:271-272.
    • (2006) Br J Haematol , vol.135 , pp. 271-272
    • Christoforidis, A.1    Perifanis, V.2    Athanassiou-Metaxa, M.3
  • 16
    • 0036431540 scopus 로고    scopus 로고
    • Monitoring chelation therapy to achieve optimal outcome in the treatment of thalassaemia
    • Porter JB, Davis BA. Monitoring chelation therapy to achieve optimal outcome in the treatment of thalassaemia. Best Pract Res Clin Haematol. 2002;15:329-368.
    • (2002) Best Pract Res Clin Haematol , vol.15 , pp. 329-368
    • Porter, J.B.1    Davis, B.A.2
  • 17
    • 0017356978 scopus 로고
    • Effect of dose, time, and ascorbate on iron excretion after subcutaneous desferrioxamine
    • Hussain MA, Green N, Flynn DM, et al. Effect of dose, time, and ascorbate on iron excretion after subcutaneous desferrioxamine. Lancet. 1977;1:977-979.
    • (1977) Lancet , vol.1 , pp. 977-979
    • Hussain, M.A.1    Green, N.2    Flynn, D.M.3
  • 18
    • 0024521376 scopus 로고
    • Desferrioxamine-induced iron excretion in humans
    • Pippard MJ. Desferrioxamine-induced iron excretion in humans. Baillieres Clin Haematol. 1989;2:323-343.
    • (1989) Baillieres Clin Haematol , vol.2 , pp. 323-343
    • Pippard, M.J.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.